Caseware UK (AP4) 2024.0.164 2024.0.164 The company has provided a loan to a company of which the directors are shareholders and directors. The amount outstanding at the financial year end was £12,770 (2024 £17,540). The company operates directors current accounts with the directors which are unsecured, interest free and repayable on demand. The amount owed to R Leckie at the financial year end was £1,599 (2024: £1,599). The amount owed to T Mitchell at the financial year end was £5,881 (2024: £5,881). The company has received loans from companies of which a director is shareholder and director. The amounts outstanding at the financial year end was £12,884 (2024 : £12,884).truefalsefalse2024-04-01No description of principal activity22trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 08098611 2024-04-01 2025-03-31 08098611 2023-04-01 2024-03-31 08098611 2025-03-31 08098611 2024-03-31 08098611 c:Director1 2024-04-01 2025-03-31 08098611 c:Director2 2024-04-01 2025-03-31 08098611 c:RegisteredOffice 2024-04-01 2025-03-31 08098611 d:Non-currentFinancialInstruments 2025-03-31 08098611 d:Non-currentFinancialInstruments 2024-03-31 08098611 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 08098611 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 08098611 d:Non-currentFinancialInstruments d:AfterOneYear 2025-03-31 08098611 d:Non-currentFinancialInstruments d:AfterOneYear 2024-03-31 08098611 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2025-03-31 08098611 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2024-03-31 08098611 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2025-03-31 08098611 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-03-31 08098611 d:ShareCapital 2025-03-31 08098611 d:ShareCapital 2024-03-31 08098611 d:RetainedEarningsAccumulatedLosses 2025-03-31 08098611 d:RetainedEarningsAccumulatedLosses 2024-03-31 08098611 c:OrdinaryShareClass1 2024-04-01 2025-03-31 08098611 c:OrdinaryShareClass1 2025-03-31 08098611 c:OrdinaryShareClass1 2024-03-31 08098611 c:FRS102 2024-04-01 2025-03-31 08098611 c:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 08098611 c:AbridgedAccounts 2024-04-01 2025-03-31 08098611 c:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 08098611 2 2024-04-01 2025-03-31 08098611 e:PoundSterling 2024-04-01 2025-03-31 xbrli:shares iso4217:GBP xbrli:pure
Registered number: 08098611










REMEDY PHYSIO LTD

Unaudited
Financial statements
Information for filing with the registrar
For the year ended 31 March 2025

 
REMEDY PHYSIO LTD
 

Company Information


Directors
R Leckie 
T Mitchell 




Registered number
08098611



Registered office
24 Wilkinson Street

Sheffield

South Yorkshire

S10 2GB





 
REMEDY PHYSIO LTD
Registered number: 08098611

Balance sheet
As at 31 March 2025

2025
2024
Note
£
£

  

Current assets
  

Debtors
  
13,966
20,284

Cash at bank and in hand
 4 
1,571
777

  
15,537
21,061

Creditors: amounts falling due within one year
  
(25,392)
(25,502)

Net current liabilities
  
 
 
(9,855)
 
 
(4,441)

Total assets less current liabilities
  
(9,855)
(4,441)

Creditors: amounts falling due after more than one year
 5 
(490)
(4,592)

  

Net liabilities
  
(10,345)
(9,033)


Capital and reserves
  

Called up share capital 
 7 
100
100

Profit and loss account
  
(10,445)
(9,133)

  
(10,345)
(9,033)


Page 1

 
REMEDY PHYSIO LTD
Registered number: 08098611

Balance sheet (continued)
As at 31 March 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 16 September 2025.




R Leckie
T Mitchell
Director
Director

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
REMEDY PHYSIO LTD
 

 
Notes to the financial statements
For the year ended 31 March 2025

1.


General information

Remedy Physio Limited is a company limited by shares and incorporated in England within the United Kingdom. The address of the registered office is given in the company information on page 1 of these financial statements.
The financial statements are presented in sterling which is the functional currency of the company.
The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A) of the Companies Act 2006.

 
2.2

Revenue

Revenue is measured at the fair value of the consideration received or receivable. The policies adopted for the recognition of turnover are as follows:
Rendering of services
Revenue is recognised in the period in which the services are provided.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.5

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.6

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 3

 
REMEDY PHYSIO LTD
 

 
Notes to the financial statements
For the year ended 31 March 2025

2.Accounting policies (continued)

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Impairment of financial assets

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss. 

Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.

If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is
Page 4

 
REMEDY PHYSIO LTD
 

 
Notes to the financial statements
For the year ended 31 March 2025

2.Accounting policies (continued)


2.9
Financial instruments (continued)

immaterial.


3.


Employees




The average monthly number of employees, including directors, during the year was 2 (2024 -2).


4.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
1,571
777

1,571
777



5.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Bank loans
490
4,592

490
4,592


Page 5

 
REMEDY PHYSIO LTD
 

 
Notes to the financial statements
For the year ended 31 March 2025

6.


Loans


Analysis of the maturity of loans is given below:


2025
2024
£
£

Amounts falling due within one year

Bank loans
4,190
4,089


4,190
4,089

Amounts falling due 1-2 years

Bank loans
490
4,192


490
4,192

Amounts falling due 2-5 years

Bank loans
-
399


-
399


4,680
8,680



7.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



100 (2024 -100) Ordinary shares of £1.00 each
100
100



8.


Related party transactions

The company has provided a loan to a company of which the directors are shareholders and directors. The amount outstanding at the financial year end was £12,770 (2024 £17,540).
The company operates directors current accounts with the directors which are unsecured, interest free and repayable on demand. The amount owed to R Leckie at the financial year end was £1,599 (2024: £1,599).  The amount owed to T Mitchell at the financial year end was £5,881 (2024: £5,881). 
The company has received loans from companies of which a director is shareholder and director. The amounts outstanding at the financial year end was £12,884 (2024 : £12,884).


Page 6